Article citationsMore>>

W. H. Wilson, “The Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Has Preferential Activity in the ABC Subtype of Relapsed/Refractory de Novo Diffuse Large B Cell Lymphoma (DLBCL): Interim Results of a MultiCenter, Open-Label, Phase II Study, in American Society of Hematology,” Blood, 2012.

has been cited by the following article:

• TITLE: Emerging Frontiers in Therapeutics of Diffuse Large B Cell Lymphoma: Epigenetics and B Cell Receptor Signaling

  AUTHORS: Soham Puvvada, Lisa Rimsza

  KEYWORDS: BCR Signaling; Epigenetics

  JOURNAL NAME: Journal of Cancer Therapy, Vol.4 No.3A, March 25, 2013

  ABSTRACT: This review discusses the impact of gene expression profiling and sequencing discoveries on new therapeutic strategies in Non-Hodgkin Lymphomas, particularly Diffuse Large B cell Lymphoma. Alterations in oncogenes, over-active signaling pathways down-stream of the B cell receptor, and epigenetic gene mutations will be described. We will also review new targeting strategies aimed at each of these aspects of cell biology encompassing BCL2, BTK, PKCβ, PI3K/mTOR and HDAC inhibition. Specific new drugs in clinical trials and early trial results are included as well.